Send to

Choose Destination
Cephalalgia. 2018 Jul;38(8):1471-1484. doi: 10.1177/0333102417737778. Epub 2017 Oct 12.

Soluble guanylyl cyclase is a critical regulator of migraine-associated pain.

Author information

1 Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, Chicago, IL, USA.
2 UICentre for Drug Discovery, University of Illinois at Chicago, Chicago, IL, USA.
3 Department of Psychiatry, University of Illinois at Chicago, Chicago, IL, USA.
4 Department of Biomedical and Molecular Sciences, Faculty of Health Sciences, Queen's University, Kingston, Canada.


Background Nitric oxide (NO) has been heavily implicated in migraine. Nitroglycerin is a prototypic NO-donor, and triggers migraine in humans. However, nitroglycerin also induces oxidative/nitrosative stress and is a source of peroxynitrite - factors previously linked with migraine etiology. Soluble guanylyl cyclase (sGC) is the high affinity NO receptor in the body, and the aim of this study was to identify the precise role of sGC in acute and chronic migraine. Methods We developed a novel brain-bioavailable sGC stimulator (VL-102), and tested its hyperalgesic properties in mice. We also determined the effect of VL-102 on c-fos and calcitonin gene related peptide (CGRP) immunoreactivity within the trigeminovascular complex. In addition, we also tested the known sGC inhibitor, ODQ, within the chronic nitroglycerin migraine model. Results VL-102-evoked acute and chronic mechanical cephalic and hind-paw allodynia in a dose-dependent manner, which was blocked by the migraine medications sumatriptan, propranolol, and topiramate. In addition, VL-102 also increased c-fos and CGRP expressing cells within the trigeminovascular complex. Importantly, ODQ completely inhibited acute and chronic hyperalgesia induced by nitroglycerin. ODQ also blocked hyperalgesia already established by chronic nitroglycerin, implicating this pathway in migraine chronicity. Conclusions These results indicate that nitroglycerin causes migraine-related pain through stimulation of the sGC pathway, and that super-activation of this receptor may be an important component for the maintenance of chronic migraine. This work opens the possibility for negative sGC modulators as novel migraine therapies.


CGRP; Trigeminovascular pain; cGMP; mouse model; nitric oxide

[Available on 2019-07-01]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center